Furthermore, mRNA transcriptomics of Gal-9 from the GSE130588 study showed that treatment with dupilumab for 16 weeks downregulated its transcriptional levels in the lesional skins from AD patients compared to control skins. This evidence concerns the gene LGALS9 and Alzheimer disease.